key: cord-0693775-iichr5ht
authors: KLEINWECHTER, Helmut J.; WEBER, Katharina S.; MINGERS, Nina; RAMSAUER, Babett; SCHAEFER-GRAF, Ute M.; GROTEN, Tanja; KUSCHEL, Bettina; BACKES, Clara; BANZ-JANSEN, Constanze; BERGHAEUSER, Martin A.; BROTSACK, Irene A.; DRESSLER-STEINBACH, Iris; ENGELBRECHT, Charlotte; ENGLER-HAUSCHILD, Sarah; GRUBER, Teresa-Mira; HEPP, Vanessa; HOLLATZ-GALUSCHKI, Elsa; IANNACCONE, Antonella; JEBENS, Anja; VON KAISENBERG, Constantin S.; KAUP, Lisa; KEIL, Corinna; KLADT, Carolin; KOLBEN, Thomas; KRAFT, Katrina; KUNZE, Mirjam; LASTINGER, Julia; LUEDEMANN, Katharina; MANZ, Jula; MORFELD, Christine A.; PARCHMANN, Olaf; PFAFF, Lena; REINHARDT, Kristin; RUNKEL, Anne; SCHMIDT, Markus; SOUROUNI, Marina; STELBRINK, Johanna; STUBERT, Johannes; STUMPFE, Florian M.; TREPTOW, Anna; RÜDIGER, Mario; PECKS, Ulrich
title: Gestational diabetes mellitus and COVID-19: results from the CRONOS study
date: 2022-05-14
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2022.05.027
sha: e9237f84764da34558f5fa414d0b079030e6b5b1
doc_id: 693775
cord_uid: iichr5ht

BACKGROUND Gestational diabetes mellitus is one of the most frequent pregnancy complications with a global prevalence of 13.4% in 2021. Pregnant women with COVID-19 and gestational diabetes mellitus are 3.3 times more likely to be admitted to an intensive care unit compared to women without gestational diabetes mellitus. Data on the association of gestational diabetes mellitus with maternal and neonatal pregnancy outcomes in SARS-CoV-2-infected pregnant women are lacking. OBJECTIVE The aim of our study was to investigate whether gestational diabetes mellitus is an independent risk factor for adverse maternal and fetal/neonatal outcomes in pregnant women with COVID-19. STUDY DESIGN CRONOS (COVID-19 Obstetric and Neonatal Outcome Study) is a registry-based multicentric prospective observational study from Germany and Linz/Austria. Pregnant women with clinically confirmed COVID-19 were enrolled between April 3, 2020 and August 24, 2021, at any stage of pregnancy. Obstetricians and neonatologists of 115 hospitals actively provided data to CRONOS. For collecting data a cloud based electronic data platform was developed. Women and neonates were followed until hospital discharge. Information on demographic characteristics, comorbidities, medical history, COVID-19 associated symptoms and treatments, pregnancy and birth outcomes were entered by the local sites. Information on the periconceptional body mass index was collected. A primary combined maternal endpoint was defined as (1) admission to an intensive care unit (including maternal mortality), and/or (2) viral pneumonia, and/or (3) oxygen supplementation. A primary combined fetal/neonatal endpoint was defined as (1) stillbirth >24+0 weeks of pregnancy, and/or (2) neonatal death <7 days postnatal, and/or (3) transfer to a neonatal intensive care unit. Multivariable logistic regression analysis was performed to evaluate the modulating impact of gestational diabetes mellitus on the defined endpoints. RESULTS Of the 1,490 women with COVID-19 (mean age 31.0 ± 5.2 years, 40.7% nulliparous), 9.4% (n=140) were diagnosed with gestational diabetes mellitus, of these, 42.9% were treated with insulin. Overall, gestational diabetes mellitus was not associated with an adverse maternal outcome (odds Ratio: 1.50; 95% confidence interval: 0.88; 2.57). In overweight/obese women, however, gestational diabetes mellitus was independently associated with the primary maternal outcome (adjusted odds ratio 2.69; 95% confidence interval: 1.43; 5.07). Overweight/obese women with gestational diabetes mellitus requiring insulin treatment were found to have an increased risk for a severe course of COVID-19 (adjusted odds ratio 3.05; 95% conficence interval: 1.38; 6.73). Adverse maternal outcome was more common when COVID-19 was diagnosed with or short after gestational diabetes mellitus diagnosis compared to COVID-19 diagnosis prior to gestational diabetes mellitus diagnosis (19.6% vs. 5.6%, p<0.05). Maternal gestational diabetes mellitus and maternal preconceptional body mass index >25 kg/m2 increased the risk of adverse fetal/neonatal outcome (adjusted odds ratio 1.83; 95% confidence interval: 1.05; 3.18). Furthermore, overweight/obesity (irrespective of gestational diabetes mellitus status) were influential factors for the maternal (adjusted odds ratio 1.87; 95% confidence interval: 1.26; 2.75) and neonatal primary endpoints (1.81; 95% confidence intervall: 1.32; 2.48) in comparison to women with underweight or normal weight. CONCLUSION Gestational diabetes mellitus, combined with periconceptional overweight/obesity, is independently associated with severe maternal course of COVID-19, especially when the mothers require insulin and COVID-19 is diagnosed with or after gestational diabetes mellitus diagnosis. These combined factors exhibited a moderate effect on neonatal outcomes. Women with gestational diabetes mellitus and body mass index >25 kg/m2 are a particularly vulnerable group in the case of COVID-19.

Introduction 196 Pregnancy is considered as an independent risk factor for severe COVID-19 1 and 197 pregnancy outcomes are negatively influenced by pre-existing comorbidities such as 198 cardiovascular disease, obesity, and diabetes mellitus (DM) 2 . Obesity is associated 199 with an unfavorable outcome in pregnant women and its combination with abnormal inflammation are independently associated with a severe course 6 . It has been 212 additionally shown that SARS-CoV-2 may damage pancreatic beta-cells, resulting in 213 an increased incidence of newly diagnosed diabetes 7,8 . 214 Little is known about the modulatory role of GDM in pregnant women with COVID-19. 215 GDM is one of the most frequent pregnancy complications with a global prevalence 216 of 13.4% and in Europe of 7.8% respectively 9,10 . Although GDM is a milder form of 217 hyperglycemia, pregnant women with COVID-19 and GDM are 3.3 times more likely 218 to be admitted to an intensive care unit (ICU) compared to women without diabetes, 219 yet in this review severe disease and invasive ventilation in women with GDM were not increased 2 . Analysis of data from registries can be skewed, either lacking specific 221 information about GDM and its differentiation from DM, or the data extraction is solely 222 based on ICD codes 11, 12, 13 . 223 For the present study, data from the "COVID-19 Obstetric and Neonatal Outcome 224 Study" (CRONOS), a hospital-based registry study in Germany and Linz/Austria, 225 were used to evaluate data on the diagnosis and treatment of GDM. The aim of this 226 subgroup analysis of the CRONOS registry was to investigate whether GDM 227 represents an independent risk factor for adverse maternal and neonatal outcomes in (Table 1) . Overall, 41% of women of the study cohort 337 were nulliparous. Low language competency, a surrogate parameter in our cohort for 338 low socio-economic status, was found in 25%. Women with GDM compared to those 339 without GDM or DM were older and more likely to be overweight or obese (Table 1) .

Associations of diabetes status with combined primary maternal endpoint 341 In the overall sample, the odds to develop the combined primary maternal endpoint 342 were comparable among women with GDM to those without any type of diabetes (model 1, Table 2 ). Women with a BMI above the normal range (≥25 kg/m 2 including 344 further stratification in overweight and obesity) compared to those with under-/normal 345 weight had significantly higher odds for the maternal endpoint (models 1, Table 2 between women with GDM, irrespective of insulin use, compared to those without 357 any type of DM (models 2 and 3, Table 2 ). In the multivariable adjusted model, the odds of developing the combined primary 361 fetal and neonatal endpoint were not different among the offspring of women with 362 GDM and those without any DM in the overall sample (model 1, Table 3 ).

Contrastingly, increased maternal BMI was associated with an approximately 80% 364 higher risk to develop the combined endpoint (models 1, Table 3 and Supplementary   365   Table 2 ). In stratified analyses, we observed a risk increment of 83% and 91% for 366 offspring of overweight/obese mothers with and without GDM, respectively, for the 367 combined fetal and neonatal endpoint, compared to offspring of mothers of the reference group (model 2, Table 3 ). There was no statistically significant difference in 369 the primary fetal/neonatal endpoint depending on the time of COVID-19 diagnosis 370 prior or with/after GDM diagnosis (24.2% vs. 21.5%) (Supplementary Table 3 ). Unlike 371 the findings for the combined maternal endpoint, offspring of mothers using insulin 372 appeared to already have an increased risk for developing the combined fetal and 373 neonatal endpoint with a maternal BMI <25 kg/m 2 (model 3, Table 3 ). Table 4 ). Moreover, our study did not include women with asymptomatic SARS-CoV-2 infection 501 or a cohort without COVID-19. This limits generalization of data to those women with 502 COVID-19 during their pregnancy. Third, we have no information on monogenic 503 diabetes but we presume from our data that the incidence is low. Lastly, some 

Update: characteristics of symptomatic